Interní Med. 2008; 10(9): 380-383

The choice of antidiabetic medications with regard to metabolic syndrome

doc. MUDr. Alena ©mahelová Ph.D
Klinika gerontologická a metabolická, FN Hradec Králové

For treatment of diabetes type 2 we dispose of effective antidiabetic medications (metformine, sulphonylurea derivates, glitazones, acarbosa) and soon further medications from group of incretine mimetics will occur. In antidiabetic medications besides the antihyperglycemic effect the effect on weight is announced but other effects are not presented. Nowadays we have evidence that antidiabetic medications have effect on other components of metabolic syndrome – hypertension, dyslipidemia, and even obesity. Even in choice of antidiabetic medications we have to pay attention to more complex effects than only decrease of blood sugar and consider especially effects on lipid spectrum and blood pressure.

Keywords: Key words: diabetes mellitus type 2, metabolic syndrome, peroral antidiabetic medications, dyslipidemia, hypertension, cardiovascular complications.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. The choice of antidiabetic medications with regard to metabolic syndrome. Interní Med. 2008;10(9):380-383.
Download citation

References

  1. Ahrén B. GLP-1-Based Therapy of Type 2 Diabetes: GLP-1 Mimetics and DPP-IV Inhibitors. Curr Diab Rep. 2007; 7 (5): 340-347. Go to original source... Go to PubMed...
  2. Danchin, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: result from a nationwide French registry. Diab Met Res Rev. 2005; 21: 143-149. Go to original source... Go to PubMed...
  3. Derosa G, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007; 30 (5): 387-394. Go to original source... Go to PubMed...
  4. Dormandy JA, Charbonnel B, Eckland DJ, et al. The PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
  5. DPP Study group: Reduction in incidence of type 2 diabetes with lifestyle intervention New Engl J. Med. 346, 2002; 393-403. Go to original source... Go to PubMed...
  6. Haberbosch W. Effects of Thiazolidinediones on Dyslipidemia in Patients with Type 2 Diabetes. Are All Equally Vasoprotective? Herz. 2007; 32 (1): 51-57. Go to original source... Go to PubMed...
  7. Haluzík M, Svačina ©. Gliptiny. In Trendy v diabetologii 12, Galén Praha, 2008.
  8. Jennings PE, Saniabadi AR, Belch JJ. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 1999; 41 (SUPL 1): 36-39. Go to original source... Go to PubMed...
  9. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006; 13: 134-137. Go to original source... Go to PubMed...
  10. Katakami N, Katakami Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamid, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004; 47: 1906-1913. Go to original source... Go to PubMed...
  11. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidindiones and fracture risk. Arch Intern Med. 2008; 28; 168 (8): 820-825. Go to original source... Go to PubMed...
  12. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-21, and Diabetes Care 2006; 29: 1963-1972. Go to original source... Go to PubMed...
  13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidindiones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31 (1): 173-175. Go to original source... Go to PubMed...
  14. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, NEJM, 2007; 356: 2457-2471. Go to original source... Go to PubMed...
  15. Pan, Xiao-Ren M, et al. Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study Diabetes Care 1997; 20: 537-544. Go to original source... Go to PubMed...
  16. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007; 30 (2): 217-223. Go to original source... Go to PubMed...
  17. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia. 2002; 45 (7): 1034-1037. Go to original source... Go to PubMed...
  18. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321, 2000: 405-412. Go to original source... Go to PubMed...
  19. ©mahelová A. Metformin. Trendy v diabetologii 12, ed. M. Haluzík, Galén 2008.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.